NKTR 424B5 SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

NKTR ▼ -23.85% at T+20d

LONG call ✗ call lost -23.85% · α vs SPY -28.49% · entry $91.26 → $69.49

Next anchor: T+60d in 8w

Last close $66.61 (close May 22) · -27.01% from $91.26 entry

Entry anchored
Apr 22, 03:59 PM ET
via Databento tick

T+1d

+0.46%

call +0.46% · α -0.32%

$91.68

settled 4w ago

T+5d

-8.83%

call -8.83% · α -10.31%

$83.20

settled 24d ago

T+20d

-23.85%

call -23.85% · α -28.49%

$69.49

settled 3d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Nektar Therapeutics is raising approximately $305.1 million through a public offering of 3.53 million common shares at $92.00 per share, with proceeds intended to fund clinical development of its lead drug candidates, including rezpegaldesleukin for autoimmune diseases and NKTR-255 for oncology. The offering follows positive Phase 2b data for rezpegaldesleukin in alopecia areata.

Actionable Insight

Monitor upcoming clinical trial milestones for rezpegaldesleukin, particularly Phase 3 initiation timelines, as successful development could validate the capital raise and drive further upside. The strong cash position reduces near-term funding risk.

Key Facts

Offering 3,532,609 shares of common stock at $92.00 per share, raising gross proceeds of $325 million
Net proceeds estimated at $305.1 million after underwriting discounts and commissions
Proceeds to be used for clinical development, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata
Recent positive Phase 2b data showed improved hair regrowth in alopecia areata patients with favorable safety profile
Company had approximately $741.7 million in cash and marketable securities as of April 1, 2026

Financial Impact

Raises $305.1 million in net proceeds, increasing cash position by approximately 41% based on current cash balance

cashdilutionmarket capitalization

Risk Factors

Dilution to existing shareholders - new investors experience $63.78 per share dilution
Clinical development risk - drug candidates may fail in later-stage trials
Market volatility - biotech stocks are particularly sensitive to clinical trial outcomes

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
424B5 Filing (Primary)	0001193125-26-171717
Document: d138057dexfilingfees.htm	0001193125-26-171717
Document: 0001193125-26-171717-index-headers.html	0001193125-26-171717
Document: 0001193125-26-171717-index.html	0001193125-26-171717
Document: 0001193125-26-171717.txt	0001193125-26-171717

8 reports for NKTR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for NKTR — sortable, filterable
	Type				Now
May 21, 2026 2d ago	Insider Cluster BEARISH ★ 5/10	—	awaiting T+5	—	—
May 8, 2026 15d ago	8-K BEARISH ★ 5/10	$78.72 $68.43	▲ +13.07%	▲ +12.99%	$66.61 (+15.38%)
May 7, 2026 16d ago	8-K NEUTRAL ★ 4/10	$81.89 $74.33	▼ −9.23%	▼ −10.70%	$66.61 (−18.66%)
Apr 24, 2026 29d ago	DEFA14A NEUTRAL ★ 3/10	$86.74 $86.89	▲ +0.17%	▼ −0.23%	$66.61 (−23.21%)
Apr 23, 2026 4w ago	8-K NEUTRAL ★ 5/10	$91.26 $83.20	▼ −8.83%	▼ −10.31%	$66.61 (−27.01%)
Apr 23, 2026 4w ago	424B5 BULLISH ★ 7/10	$91.26 $83.20	▼ −8.83%	▼ −10.31%	$66.61 (−27.01%)
Apr 20, 2026 4w ago	424B5 MIXED ★ 6/10	$98.16 $83.81	▼ −14.62%	▼ −15.70%	$66.61 (−32.14%)
Apr 20, 2026 4w ago	8-K NEUTRAL ★ 3/10	$98.16 $83.81	▼ −14.62%	▼ −15.70%	$66.61 (−32.14%)

US Market Status

Market Closed — Opens Tue (34h 49m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access